Issue Date: April 20, 2009
Paying Attention To Neglected Diseases
IN FEBRUARY, when Andrew Witty, chief executive officer of GlaxoSmithKline, announced measures his company would take to develop and offer drugs for neglected diseases in the poorest countries, he received a lukewarm response from Médecins sans Frontières (Doctors Without Borders). The Nobel Prize-winning activist group criticized what it called a lack of details, adding that the patent pool Witty proposed should also include intellectual property (IP) related to HIV/AIDS.
Although the . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society